Indegene Limited , a leading digital-first, life sciences commercialization company, reported its financial results for the first quarter, showcasing steady growth and strategic initiatives.

Financial Highlights

• Revenue reached INR 7,068.00 million, representing a 1.8% growth in USD terms and 0.7% in INR terms quarter-on-quarter.
• EBITDA stood at INR 1,536.00 million, with a 0.7% quarter-on-quarter growth.
• Profit After Tax (PAT) came in at INR 1,164.00 million.
• Cash and cash equivalents investments crossed $200 million, reaching INR 17,280.00 million.

Strategic Developments

Indegene introduced 'Tectonic', a new commercial content creation initiative that generated over USD 1.00 million in revenue from two top-20 customers during the quarter. This initiative aims to move up the marketing value chain and capture more upstream work traditionally done by specialized healthcare agencies.

Segment Performance

• Enterprise segments (Enterprise Commercial Solutions and Enterprise Medical Solutions) contributed 86.6% of revenue and grew 3.5% quarter-on-quarter.
• Brand Activation segment (formerly Omnichannel Activation) experienced a 21.6% degrowth due to project deferrals from regulatory hurdles and project conclusions.

Client Metrics

• The largest customer grew by 4.3% quarter-on-quarter.
• Top 5 accounts showed a 0.6% growth, reversing the previous quarter's trend.
• The company secured two large deal wins exceeding USD 3.00 million Annual Contract Value (ACV) and four deals in the USD 1.00-3.00 million range.

Industry Outlook and AI Integration

Manish Gupta, Chairman and CEO of Indegene, commented on the industry outlook: "We see no change in the industry outlook. Directionally, the pressure remains on drug pricing and hence, pharma operations to be more efficient."

The company is actively incorporating AI into its solutions across medical affairs, regulatory, safety, and commercial operations through its Cortex platform. This integration is expected to play a significant role in differentiating Indegene and enabling it to capture a larger market share in the medium term.

Future Focus

Indegene's management emphasized their commitment to growth and reinvestment in capabilities such as Tectonic and AI integration. The company aims to maintain EBITDA margins around 20% in the near term while focusing on revenue growth and market expansion.

As the life sciences industry continues to evolve, Indegene remains well-positioned to capitalize on the increasing demand for digital-first, AI-enabled solutions in commercialization and operations.

Indegene Limited , a digital-first life sciences commercialization company, has announced its financial results for the first quarter of fiscal year 2026, along with key strategic initiatives aimed at driving future growth.

Financial Highlights

Indegene reported a consolidated revenue of ₹7,608 million for Q1 FY26, representing a 1.8% quarter-on-quarter (QoQ) growth in USD terms and a 12.5% year-on-year (YoY) increase. The company maintained a strong profitability profile with an EBITDA margin of 20.2% and a PAT margin of 15.3%.

Key financial metrics for Q1 FY26:

Segment Performance

Indegene's business segments showed mixed performance:

1. Enterprise Commercial Solutions (ECS): Revenue of ₹4,453 million, up 4.6% QoQ
2. Enterprise Medical Solutions (EMS): Revenue of ₹2,132 million, up 1.2% QoQ
3. Brand Activation: Revenue of ₹758 million, down 21.6% QoQ due to project delays and conclusion of a large project

Strategic Growth Initiatives

Manish Gupta, Chairman and CEO of Indegene, outlined several strategic focus areas for FY26:

1. Tectonic Initiative: This strategic program aims to move Indegene upstream in the marketing value chain for commercial content creation. It has already started generating revenue, contributing over $1 million across two customers in Q1.

2. Sales and Go-to-Market Reorganization: The company has implemented a strategic review of account coverage and remapped its approach to maximize breadth and depth of coverage. Separate teams now focus on large deals and growth accounts.

3. Business Capability Enhancement: Indegene is strengthening its ECS and EMS capabilities by onboarding senior talent in Data & Analytics, Content, Medical Affairs, and Regulatory Affairs.

4. Consulting Practice Repositioning: The consulting practice has been given a broader remit with more strategic involvement in engagements for better client management and change management handling.

5. Operational Excellence: Indegene is implementing the Malcolm Baldrige Model to drive operational excellence across the organization.

6. M&A Focus: The company has identified priority areas for mergers and acquisitions, including Data & Analytics capability enhancement, Medical capability enhancement, and Business IT implementation. A dedicated team of 10 people is involved in M&A efforts.

Management Commentary

Manish Gupta, Chairman and CEO, commented: "We continued our growth momentum in Q1FY26, delivering 1.8% growth QoQ in USD. This reflects a strong start to the year and indicates good traction with our clients and from recent deal wins. This was a good quarter for new pipeline growth, and we maintained the momentum on deal wins as well."

Suhas Prabhu, CFO, added: "In Q1FY26, we maintained our trajectory of stable and profitable growth. Both EBITDA margins and PAT margins were on stable lines, even as we continued investing in scaling Tectonic engagements. We have a strong cash position and balance sheet and remain focused on M&A opportunities."

Industry Recognition

Indegene continues to gain recognition in the industry:

• Named a Leader in Life Sciences AI and Analytics Services by Everest Group
• Identified as a Leader in ISG's Provider Lens™ Evaluation for Life Sciences Digital Services in Commercial Operations
• Recognized as an Innovator in Veeva Services 2025 RadarView™ by Avasant

As Indegene implements its strategic initiatives and focuses on expanding its capabilities, the company aims to strengthen its position in the life sciences commercialization market and drive sustainable growth in the coming quarters.